ReviewReviews in endocrine & metabolic disorders2025
Pathophysiological insights into asprosin: an emerging adipokine in reproductive health.
Review in Reviews in endocrine & metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Expression of asprosin and OLFR734 in reproductive tissues of polycystic ovary syndrome mice: insights into metabolic and reproductive dysfunction.Cell and tissue research · 2026Article
- Umbilical cord asprosin and subfatin levels in relation to neonatal metabolic outcomes in gestational diabetes mellitus: a cross-sectional study.BMC endocrine disorders · 2026Article
- Beyond glycemia: adropin, asprosin, and irisin as potential biomarkers for cardiovascular risk in diabetes and prediabetes.Scientific reports · 2026Article
- Dysregulation of adipokines in the serum of breast cancer patients - role in pathogenesis and potential clinical application (preliminary studies).Frontiers in immunology · 2026Article
- Investigation of endocrine and cerebral response and nutrition and physical performance parameters according to bigorexia nervosa levels: a cross-sectional study in sports sciences faculty students.Scientific reports · 2025Article
- Evaluating plasma adipokines and their cognate receptors as biomarkers for non-invasive diagnosis of endometrial cancer.Bioscience reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Asprosin is a versatile protein hormone primarily produced by white adipose tissue (WAT). When secreted into the bloodstream, it exerts a range of central and peripheral effects, positioning it as a key player in metabolic processes. Since its discovery, asprosin has garnered increasing attention for its involvement in metabolic disorders, such as insulin resistance (IR) and inflammation, both of which are critical to reproductive health. Emerging evidence indicates that asprosin influences the hypothalamus-pituitary-gonadal (HPG) axis, a key neuroendocrine system regulating mammalian reproduction. Concurrently, clinical studies have revealed dysregulated asprosin expression in various reproductive diseases, including polycystic ovary syndrome (PCOS), breast cancer, ovarian cancer, and pregnancy-related disorders such as gestational diabetes mellitus (GDM) and preeclampsia. These findings suggest that asprosin plays a crucial role in reproductive events and infertility-related conditions. This review provides an overview of the latest research on asprosin's role in reproduction, female reproductive diseases, and pregnancy complications, while also outlining potential future research directions. A deeper understanding of asprosin's complex involvement in reproduction and reproductive-endocrine disorders could offer novel insights into its potential as a therapeutic target for addressing infertility in clinical settings.
Indexed as
Identifiers
40488997What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.